Division of Urology, University Health Network and Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Urol Oncol. 2010 Mar-Apr;28(2):197-204. doi: 10.1016/j.urolonc.2009.08.015.
Prostate cancer remains a challenge due to its incidence and radical prostatectomy continues to be a major treatment option for men with potentially curable disease who have a life expectancy over a decade. This article will address the common problem of positive surgical margins and the impact of them on patient outcome. Through these we can examine relevant clinical trials that have attempted to address this issue and offer some guided to therapy among men with this clinical problem. Close margins are probably of no significance and will not be addressed. Our recommendations take into account the current level of medical evidence, and are balanced with anticipated adverse effects of treatment. They may change over time once definitive clinical trials are completed. In brief we believe those with positive margins and PT2 we advocate close observation with the aim of early salvage radiotherapy if necessary. Those with PT3a and focally positive margins with low/intermediate grade tumors are at moderate risk of biochemical failure so should be managed like PT2 patients. However those with high-grade disease should be offered adjuvant radiotherapy. Similarly those with PT3a margin positive extensive or multiple site disease should have adjuvant radiotherapy. PT3B margin positive patients should be offered radiotherapy. PT4 with bladder neck only margin positive can probably be observed.
前列腺癌仍然是一个挑战,因为其发病率高,根治性前列腺切除术仍然是有潜在治愈可能且预期寿命超过十年的男性的主要治疗选择。本文将讨论阳性手术切缘的常见问题及其对患者预后的影响。通过这些,我们可以检查试图解决这个问题的相关临床试验,并为有这种临床问题的男性提供一些治疗指导。切缘接近通常无明显意义,故不予以讨论。我们的建议考虑了当前的医学证据水平,并与治疗的预期不良反应相平衡。一旦完成了明确的临床试验,它们可能会随着时间的推移而改变。简而言之,我们认为对于那些有阳性切缘和 PT2 的患者,我们主张密切观察,如果需要,早期进行挽救性放疗。对于那些 PT3a 和局灶性阳性切缘、肿瘤分级低/中级的患者,生化失败的风险中等,因此应像 PT2 患者一样进行管理。然而,对于高级别疾病的患者,应提供辅助放疗。同样,对于 PT3a 切缘阳性广泛或多处病变的患者,应进行辅助放疗。PT3B 切缘阳性的患者应接受放疗。对于仅膀胱颈部阳性切缘的 PT4 患者,可能可以进行观察。